Abstract
In Reply.— We thank Michaels and Cameron for their interesting letters in which they made a very important distinction in the role of somatostatin and somatostatin analogues in the treatment of diabetic diarrhea as used in our article. 1 We humbly accept the correction for using somatostatin and the somatostain analogue, octreotide, interchangeably in our article. Micheals and Cameron are correct in stating that Tsai et al 2 used the somatostatin analogue, octreotide, at a dose of 50 to 75 μg (not milligrams) by subcutaneous injection twice a day. We also point out an error in the dose of clonidine as quoted in our article. Clonidine is used at an average daily dose of 0.1 mg (not 1 mg). We apologize for the typographical error.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
